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ABSTRACT
Objective: Cervical cancer is a huge public health issue in Morocco which represents the second most
frequent and fatal cancer among women. Countries that have not yet introduced the HPV vaccine
could benefit greatly, but before implementation it is necessary to perform country-specific economic
assessments that include current screening practices.
Methods: A Markov model was developed to simulate the natural history of HPV and cervical cancer
so as to calculate the long-term health benefits and costs of HPV vaccination and current screening
by visual inspection with acetic acid (VIA). Starting from a previous transition probability matrix used
for a model from Spain, the present model was calibrated to cervical cancer incidence from Morocco.
Cost survey data was used to estimate the cost of screening and clinical procedures from the public
healthcare perspective. Incremental cost-effectiveness ratios were calculated as 2018US$ per additional
year of life saved (YLS) and both costs and health outcomes were discounted at 3%.
Results: The expected reduction in lifetime risk of cervical cancer for current screening would be 14%
at a cost of US$551/YLS compared with no intervention, assuming VIA every 3 years in women aged
30–49 at 10% coverage. HPV vaccination of pre-adolescent girls at 70% coverage would reduce the
lifetime risk of cervical cancer by 62% at a cost of US$1,150/YLS, compared with no intervention.
When implementing HPV vaccination in combination with current screening, vaccination would be
dominated, and the combined strategy would provide a 69% reduction at a cost of US$2,843/YLS,
compared with screening alone. Current screening would be dominated by vaccination when screen-
ing coverage is higher than 15%, whereas the combined strategy rapidly exceeds US$4,000/YLS.
Conclusions: HPV vaccination could be highly effective and cost-effective in Morocco. Current screen-
ing would be good value for money compared with no intervention, but scaling-up screening cover-
age would make it inefficient compared with vaccination.
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Cost-effectiveness analyses are increasingly required in the
healthcare decision-making process for the purpose of
informing about which new products to include in national
public healthcare systems or optimizing those that already
exist1. Mathematical models are commonly used in these
analyses to simulate diseases and the long-term health out-
comes and economic impact of different interventions that
cannot be explored through experimental studies. The ultim-
ate goal is to determine a set of strategies that result in
good value for money.
Cervical cancer is the third most common cancer among
women worldwide, and this health issue mostly occurs
(85%) in low- and middle-income countries, accounting for
nearly 12% of all female-related cancers2. In Morocco, cer-
vical cancer ranks second among women with an age-stand-
ardized incidence rate of 17.2 per 100,000 women and an
age-standardized mortality rate of 12.6 in 2018. There are
currently more than 200 virus strains of human papillomavi-
rus (HPV) classified according to the degree of carcinogenesis
risk, of which at least 13 are cancer-causing3. HPV types 16
and 18 are the most virulent and are responsible for 70% of
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cervical cancer cases globally, as well as a varying proportion
of other cancer and non-cancer diseases4,5.
Screening activities have showed that early detection can
reduce the morbidity and mortality associated with cervical
cancer6. Several screening tests with different performances in
terms of sensitivity and specificity are currently available, such
as the Pap smear, visual inspection with acetic acid (VIA) and
HPV DNA. In Morocco, opportunistic cervical cancer screening
based on VIA every 3 years in women aged 30–49 was
launched in 20107,8. However, the coverage rate at the
national level is only 6–10% of the targeted women, with
80–90% of all cervical cancer cases being diagnosed at an
advanced stage7,9,10. This low coverage rate might be
explained by the lack of mass communication and public
awareness campaigns about the cervical cancer screen-
ing program7.
Three prophylactic vaccines against HPV infections are
currently available and have proved to be highly safe and
effective for the prevention of HPV vaccine-type infection
and associated diseases11. The bivalent vaccine protects
against HPV types 16 and 18; the quadrivalent vaccine pro-
tects against HPV types 6, 11, 16, and 18; and the nonavalent
vaccine targets the same HPV types as the quadrivalent vac-
cine as well as types 31, 33, 45, 52, and 58. The World Health
Organization (WHO) points out that developing countries
with difficulties in implementing screening programs might
reap an important benefit from HPV vaccination as a primary
prevention strategy for cervical cancer disease12,13.
On this basis, health policy decision-makers in countries
like Morocco need to know the cost-effectiveness of HPV
vaccination to decide the best way to allocate their scarce
healthcare resources. Hence, the aim of this project is to
assess the cost-effectiveness of implementing an HPV vaccin-
ation program in Morocco and the current screening with




A Markov model was developed to simulate the natural his-
tory of HPV infection and cervical cancer in order to calculate
the long-term health benefits and costs of different cervical
cancer preventive strategies. As shown in Supplementary
Figure S1, the static model includes 12 boxes that represent
mutually exclusive health states (healthy, HPV infection, cer-
vical intraepithelial lesions (CIN) grade 1–3, International
Federation of Gynecology and Obstetrics (FIGO) cervical can-
cer stages, survival, cervical cancer mortality, and mortality
from other causes). Women move from one health state to
another in 1-year intervals according to some transition
probabilities. All women start the model simulations as
healthy and can move to the HPV-infected state by acquiring
the infection with some probability. Women who have
acquired HPV infection could develop CIN, and those with
CIN 1 or with CIN 2/3 could progress, regress, or stay in the
same state. Once in the cancer state, a woman may not
regress to other health states, and instead progresses
through the four FIGO stages. Women may die from cervical
cancer in the cancer stages, or may die from other non-
cervical cancer causes in every health state and every cycle.
The model was developed with Microsoft Excel 2010.
Calibrating the model
For our initial calibration step, a transition probability matrix
from a previous validated model for Spain was used to
reproduce cervical cancer incidence from Morocco14,15. To
ensure that the model fits the epidemiological data from
Morocco, a manual calibration process was performed to
reduce uncertainty in transition probabilities selected from
various studies. The model was calibrated to reproduce age-
specific cervical cancer incidence prior to launching the
screening program in 2010 (Supplementary Figure S2).
Strategies considered
Three cervical cancer preventive strategies were included in
the base-case analysis: current screening in Morocco of
women aged between 30 and 49 years with a VIA test every
3 years at 10% coverage rate; HPV 16/18 vaccination of pre-
adolescent girls at 14 years old with two doses at 70% cover-
age rate assuming 90% efficacy and lifelong immunity; and
combined vaccination and screening.
Demographic and epidemiological data
The distribution of the Moroccan female population by age
group was extracted from the United Nations’ population
prospects for 201516. Annual transition probabilities depict-
ing the natural history of cervical cancer and HPV infection
were also extracted from published epidemiologic articles
under the assumption that the mechanism of cervical car-
cinogenesis from initial infection is universal and that it does
not differ greatly between countries17–20. Epidemiological
data on cervical cancer incidence and mortality by age were
derived from the cancer registries of the Grand Casablanca
Region and from the ICO-HPV Information Center21,22. The
sensitivity and specificity of VIA were derived from a system-
atic review conducted to compare the test accuracy of the
HPV DNA test, cytology, and VIA23. The baseline assumptions
on screening and vaccination are shown in Table 1.
Economic data
Since it is important to use country-specific information but
there is a lack of data on costs related to cervical cancer
screening procedures in Morocco, a survey was carried out
to estimate the direct medical costs of screening, diagnosis,
and treatment of pre-cancerous lesions using loop electrosur-
gical excision procedure (LEEP) and treatment of cervical can-
cer from the public healthcare perspective in 2015 Moroccan
dirhams. The data collection and cost calculation methods
are both included in the Supplementary Appendix. All costs
were converted to 2018US dollars (US$) using GDP deflators
and average annual exchange rates24 (Table 1).
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The lower price reported for HPV vaccine was offered by
Merck to the Global Alliance for Vaccines and Immunizations
(GAVI) for the poorest countries (US$4.50 per dose), but
Morocco is not eligible for GAVI support25. The negotiated
price by the Revolving Fund of the Pan American Health
Organization (PAHO) for low- and middle-income countries
in Latin America is US$10–US$15 per dose26. Based on this,
we assumed an initial vaccine cost of US$10 per dose and a
US$5 administration cost.
For the purpose of identifying those strategies that
appear to be relatively good value for money, usually a cost-
effectiveness threshold is defined. However, there is no uni-
versal criterion and there is no consensus on how it should
be derived27. For illustrative purposes, the approach of the
Commission on Macroeconomics and Health was used, since
there is no specific local threshold defined for Morocco28,29.
This heuristic suggests that an intervention should be
considered highly cost-effective if the ICER is less than the
country’s per capita gross domestic product (GDP) and cost-
effective if the ICER is less than three times the per capita
GDP. The estimated per capita GDP in Morocco for the year
2018 is US$2,86024.
Outcomes, measurements, and cost-
effectiveness analysis
For each strategy, the model predicts the life expectancy (LE)
and the lifetime cost per woman. The incremental cost-
effectiveness ratio (ICER) was the measurement used to
perform the cost-effectiveness analysis, defined as the differ-
ence in cost between two interventions, divided by the dif-
ference in health (LE in our case). Therefore, the ICER
represents the incremental cost associated with one add-
itional year of life saved (YLS). Both cost and health out-
comes were discounted at an annual rate of 3%. To identify
which parameters and assumptions are the most influential
in the results, one-way and two-way sensitivity analyses were
carried out for the vaccination’s coverage and cost, as well
as for the coverage, sensitivity, and cost of the VIA test.
Results
The expected reduction in lifetime risk of cervical cancer for
current screening is 14% compared with no intervention,
assuming VIA every 3 years in women aged 30–49 at 10%
coverage (Figure 1). Pre-adolescent vaccination alone has an
important impact on lifetime risk of cervical cancer, reducing
it by 63% compared with no intervention and by 48% com-
pared with VIA every 3 years. An additional reduction of 7%
is also obtained when combining vaccination with the exist-
ing screening program compared with vaccination alone.
A cost-effectiveness analysis was performed, comparing
the current screening in Morocco using VIA every 3 years
with different frequencies of screening. It was found that, as
the frequency increases, both the effectiveness and the costs
rise, and screening with VIA at any frequency would be
dominated by VIA once-in-a-lifetime that would be cost-sav-
ing compared with no intervention (Table 2A). Vaccination
alone at a 70% coverage rate would cost US$1,150 per YLS
compared with no intervention (Table 2B), well below the
per capita GDP threshold. The current screening program
with VIA in Morocco (10% coverage to women aged 30–49
years) would cost US$551 per YLS compared with no inter-
vention (Table 2C). When implementing HPV vaccination in
combination with existing screening, vaccination alone
would be dominated, and the combined strategy has an
incremental cost-effectiveness ratio of US$2,843 per YLS
compared with screening alone, which would be considered
cost-effective based on the GDP per capita threshold
(Table 2C). When the screening coverage rate is higher than
15%, vaccination is no longer dominated, instead screening
alone is dominated and the ICER for the combined
Table 1. Baseline assumptions and direct medical costs indexed at year 2018.
Variable Value Range of values used in the sensitivity analysis
Baseline assumptions
VIA screening coverage 10% 5–70%
Sensititvity of VIA test 69% 30–80%
Sensititvity of colposcopy 95%
Vaccination coverage 70% 30–100%
Vaccine protection against HPV 16/18 90%
Duration of HPV 16/18 protection Lifelong
Direct medical costs (US$2018)





Procedure of CIN1 63.7
Procedure of CIN2/3 136.7
Cancer treatment
Stage I & II 1,026.9
Stage III 2,083.9
Stage IV 1,508.5
HPV vaccine cost per dose
Vaccine 10.0 5.0–35.0
Administration 5.0
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strategy increases rapidly, exceeding US $4,000/YLS above
20% (Table 2D and Supplementary Table S4).
The one-way sensitivity analysis shows that the cost-
effectiveness of adding vaccination to the existing screening
program remains relatively stable on varying the cost per
dose up to current tender prices in high-resource countries
(US$35 per dose) and vaccination coverage (up to 100%);
in neither case does the ICER exceed the per capita GDP.
The combined strategy is also stable on varying the sensitiv-
ity of the VIA test and the cost of VIA, whereas it is sensitive
to the increase in coverage of the VIA test (Figure 2)30.
Indeed, when the coverage of VIA goes from 5% to 100%,
the ICER jumps from US$997 per YLS to US$5,702 per YLS
compared with no intervention, exceeding the per capita
GDP threshold at a 50% coverage rate unless the cost of the
VIA test drops by one third (Supplementary Figure S3). At
coverage of 75%, the combined strategy exceeds the per
capita GDP threshold unless the cost of the VIA test drops
by one half. At the current price, the ICER for the combined
strategy is below three times the per capita GDP, even at
100% coverage. The slight variation on the sensitivity of the
VIA test is due to the low coverage rate of 10% assumed for
the current existing screening and the small population cov-
ered (from 30 to 49), which excludes most of the female
population at risk for cervical cancer from screening.
Discussion
Our results show that scaling up coverage of screening with
VIA more than 15% in Morocco is not cost-effective, whereas
HPV 16/18 vaccination for pre-adolescent girls at age 14 with
a coverage rate of 70% is highly cost-effective and could
reduce cervical cancer by 63%. Provided the cost per vacci-
nated girl is US$10 per dose, we have found that vaccination
alone costs US$1,150 per YLS, well below the 2018 per capita
GDP (US$2,860). Even when the vaccine cost per dose is
increased up to current tender prices in high-resource coun-
tries, pre-adolescent HPV vaccination would be considered
good value for money. The existing screening program with
VIA every 3 years for women aged between 30 and 49 years
at 10% coverage costs US$551 compared with no interven-
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Figure 1. Estimated impact on cervical cancer incidence for different strategies.
Table 2. Discounted life expectancy (LE), discounted total lifetime cost per woman, and incremental cost-effectiveness ratio for evaluated strategies.
Strategy Discounted cost per woman (US$) Discounted LE ICER (US$/YLS)
A. VIA screening alone by frequency at 10% coverage
No intervention 3.49569 54.95990
20y-VIA screening (once-in-a-lifetime) 2.48417 54.97585 CS
10y-VIA screening (twice-in-a-lifetime) 3.76766 54.97547 Dominated
5y-VIA screening (four times-in-a-lifetime) 6.97354 54.97526 Dominated
3y-VIA screening (seven times-in-a-lifetime) 11.70498 54.97480 Dominated
B. Vaccination alone at 70% coverage
No intervention 3.49569 54.95990
Vaccination (girls 14 years old) 22.36102 54.97630 1,150
C. VIA screening at 10% coverage and vaccination at 70% coverage
No intervention 3.49569 54.95990
3y-VIA screening (seven times-in-a lifetime) 11.70498 54.97480 551
Vaccination (girls 14 years old) 22.36102 54.97630 Dominated
Vaccination þ 3y-VIA screening (seven times-in-a-lifetime) 32.06297 54.98196 2,843
D. VIA screening and vaccination, both at 70% coverage
No intervention 3.49569 54.95990
3y-VIA screening (seven times-in-a-lifetime) 73.61780 54.97157 Dominated
Vaccination (girls 14 years old) 22.36102 54.97630 1,150
Vaccination þ 3y-VIA screening (seven times-in-a-lifetime) 95.05145 54.98143 14,170
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with vaccination at US$10 per dose and 70% coverage rate
when coverage of VIA is higher than 15%. The high cost of
screening and subsequent follow-up and treatment together
with an inefficient screening with VIA and low coverage in a
small fraction of women at risk of cervical cancer makes
screening alone unattractive in Morocco compared to HPV
vaccination at reasonably low prices. Vaccination combined
with existing screening practices in Morocco costs US$2,843
per YLS, which is less than Morocco’s per capita GDP. The
higher the screening coverage, the greater the ICER, exceed-
ing the per capita GDP threshold at a 50% coverage rate
unless the cost of the VIA test drops by one third.
To our knowledge, our study is the first cost-effectiveness
analysis calibrated to the Moroccan context that takes into
account the existing screening program. Only a simple Excel-
based model was used to project the population-level health
and economic impact of preadolescent HPV vaccination in 20
countries, including Morocco31. However, this model was not
calibrated to Morocco and did not include screening strat-
egies. The authors conclude that HPV vaccination would be
cost-saving at a cost of $5 per dose, cost-effective at a cost of
$26.75 per dose, and would exceed the cost-effectiveness
threshold at a cost of $54.25 per dose. The calibration proced-
ure is a crucial aspect for the model’s performance, especially
when it involves policy decisions15. Several cost-effectiveness
analyses in low- and middle-income countries have examined
the value of HPV vaccination in combination with VIA32–36. All
of these studies are in line with our results, considering HPV
vaccination to be cost-effective in resource-poor settings if the
vaccine cost decreases significantly in relation to the current
out-of-pocket price. In such circumstances, the best cervical
preventive option would be a combined strategy of VIA
screening with HPV vaccination.
The WHO recommends introducing the HPV vaccines
into national immunization programs and using VIA in
resource-constrained settings11,37. However, if HPV testing is
feasible, the WHO suggests a strategy of screening with an
HPV test over a strategy of screening with VIA. This is
increasingly achievable, since new methods of HPV testing
for low-resource settings that require low staff qualifications
are being developed, alongside alternative sample collection
methods such as cervical specimen self-sampling38.
Furthermore, based on estimates of the manufacturing costs
of HPV vaccines, the price for the GAVI alliance for introduc-
ing the HPV vaccine in the poorest countries could be
around $0.50 per dose; much lower than the current price of
$4.5039. The same study states that prices for lower- and
middle-income countries could also be lowered.
Although there have been more studies on cervical cancer
prevention in Africa in recent years, there are still several
countries with little to no research ever conducted in this
area40. Given the substantial morbidity and mortality caused
by this cancer in this setting, more research is needed to
inform about which feasible, sustainable strategies can maxi-
mize women’s health. Our analysis is the first attempt to
assess the epidemiologic and economic impact of HPV vac-
cination and existing screening practices in Morocco. The
ultimate aim is to provide information in the long-term on
value for money for cervical cancer prevention strategies in
Morocco to help decision-makers who have to work on pri-
oritization of public health investment.
There are several limitations to our approach, including
the model’s structure, input data, assumptions, and uncer-
tainty of the parameters. Some of these are inherent in deci-
sion-analytic models and were addressed following scientific
criteria of good practices or using standard approaches41,42.
Incremental cost-effecveness rao (US$/YLS)
“Vaccinaon followed by 3y-VIA screening” 
compared to 
“No intervenon”


















Figure 2. One-way sensitivity analysis for vaccination followed by screening with VIA performed every 3 years.
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For example, our model inevitably requires assumptions
about the costs of interventions and procedures, the effect-
iveness of VIA screening and vaccination, and about cervical
cancer incidence and HPV prevalence data. As the quality of
the results is only as good as the quality of the assumptions
and synthesized data, the most reliable information from
Morocco was included in the model43. Subsequently, to
ensure the credibility of the results, model predictions on
cervical cancer incidence were calibrated to real empirical
data from Morocco. In addition, sensitivity analyses were per-
formed which can help appreciate the impact of uncertain-
ties in the key parameters. However, some other limitations
are more difficult to address. For example, our model does
not capture herd immunity effects, nor does it include the
potential benefits of vaccination on other non-cervical HPV-
related diseases such as other anogenital cancers or genital
warts, and it does not reflect the impact of cross-protection
against other non-vaccine HPV types. These limitations may
lead the health benefits of HPV vaccination to be under-esti-
mated. Further, as our model is a simple representation of
the natural history of HPV infection and cervical cancer and
not a detailed model with screening complex strategies that
incorporate different visits, all women diagnosed with a CIN
lesion are treated and there is no loss-to-follow-up. In order
to deal with all these issues, it would be necessary to use
more complex approaches such as dynamic microsimulation
models. Another limitation is that our analysis is carried out
under the favorable assumption of high efficacy against HPV
16/18 with two doses; therefore, any evidence regarding the
reduction of the efficacy in two doses, the inclusion of wan-
ing immunity or the need for a booster to obtain long-term
protection would lead to less attractive results for HPV vac-
cination. Finally, although the threshold based in the GDP is
often used in cost-effectiveness analysis in low- and middle-
income countries, recent papers suggest that thresholds rep-
resenting likely health opportunity costs tend to be below
one GDP per capita44,45. In our analysis, the ICER for vaccin-
ation represents an eleventh of the per capita GDP in
Morocco, which may indicate that vaccination would be
cost-effective with a much lower threshold; whereas the ICER
for combined vaccination and existing screening with VIA
and low coverage is between one and two times the per
capita GDP, which may indicate that it could be displacing
more health than it generates.
Conclusions
Based on our results, healthcare policymakers in Morocco
should explore the possibility of supporting the implementa-
tion of pre-adolescent HPV vaccination for girls. However,
they should also consider that introducing HPV vaccine into
a national immunization program depends not only on the
cost-effectiveness, but also on other important factors such
as affordability, sustainable financing, avertable burden, feasi-
bility, and equity. Further analyses with more complex
approaches that include other non-cervical HPV-related dis-
eases, vaccines that provide protection against more high-
risk HPV types, and other screening tests such as HPV testing
as suggested by the WHO are needed in order to reconfirm
our results and to help guide the next steps on cervical can-
cer prevention in Morocco. Finally, a country like Morocco,
where there has been problems with screening coverage,
should also consider evaluating the cost-effectiveness of HPV
self-collection, which has demonstrated to be a powerful
tool to increase coverage and has the potential to overcome
many of the barriers shown by other screening techniques.
Transparency
Declaration of funding
This work was partially supported by grants from the Instituto de Salud
Carlos III through the projects RD12/0036/0056, PI11/02090, PIE16/00049,
and PI16/01254 (Co-funded by European Regional Development Fund.
ERDF, a way to build Europe). With the support of the Secretariat for
Universities and Research of the Department of Business and Knowledge
of the Government of Catalonia. Grants to support the activities of
research groups (SGR 2017–2019). Grant number 2014SGR756,
2014SGR1077 and 2017SGR1718. The research leading to these results has
received funding from the European Union’s Seventh Framework
Programme (FP7/2007–2013) under grant agreement n Health-F3-2013-
603019 (COHEAHR) and MNSIRSES [FP7-People-2013-IRSES612216]. The
research leading to these results has received funding from RecerCaixa
[2015ACUP00129]. We thank CERCA Programme/Generalitat de Catalunya
for institutional support and Lalla Salma Foundation for the Prevention
and Treatment of Cancers for financial and technical support. None of
these entities played a role in data collection or analysis, or in the inter-
pretation of the results.
Declaration of financial/other relationships
WM, TE, CN, NT, AZ, GA, DM and MD state that they have no competing
personal or financial interests in relation to this study. MD-Institutional
support: The HPV vaccine trials and epidemiological studies were spon-
sored by GlaxoSmithKline (GSK), Merck, Roche, and Sanofi Pasteur MSD.
A peer reviewer on this manuscript has disclosed being a principal
investigator of several HPV screening projects sponsored in part by BD
Diagnostics, receiving honoraria from BD Diagnostics, being a principal
investigator of EU HORIZON2020 SME contract 666-800, principal investi-
gator of study sponsored in part by Agena Biotech, Genomica SAU, and
Life River Biotech. The peer reviewers on this manuscript have no other
relevant financial relationships or otherwise to disclose.
Ethics approval and consent to participate
This manuscript has been revised for its publication by the Clinical
Research Ethics Committee of Bellvitge University Hospital. Verbal
informed consent was obtained from all participants in this study. Data
of participants were anonymized for the purposes of this analysis. The







[1] Rawlins MD. Crossing the fourth hurdle. Br J Clin Pharmacol.
2012;73:855–860.
1158 W. MESSOUDI ET AL.
[2] Ferlay J, Colombet M, Soerjomataram I, et al. Global Cancer
Observatory: Cancer Today. Lyon, France: International Agency
for Research on Cancer; 2018 [cited 2018 Oct 15]. Available from:
https://gco.iarc.fr/today.
[3] Papillomavirus Episteme (PaVE). National Institutes of Health (NIH),
National Institute of Allergy and Infectious Diseases (NIAID). [cited
2019 May] Available from: https://pave.niaid.nih.gov/#home.
[4] Clifford GM, Smith JS, Plummer M, et al. Human papillomavirus
types in invasive cervical cancer worldwide: a meta-analysis. Br J
Cancer. 2003;88:63–73.
[5] Mu~noz N, Bosch FX, de Sanjose S, et al. Epidemiologic classifica-
tion of human papillomavirus types associated with cervical can-
cer. N Engl J Med. 2003;348:518–527.
[6] Vaccarella S, Franceschi S, Engholm G, et al. 50 years of screening
in the Nordic countries: quantifying the effects on cervical cancer
incidence. Br J Cancer. 2014;111:965–969.
[7] Selmouni F, Sauvaget C, Belakhel L, et al. Organization and evalu-
ation of a pilot cervical cancer screening program in Morocco. Int J
Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet. 2016;132:25–28.
[8] Selmouni F, Belakhel L, Sauvaget C, et al. Evaluation of the
national cervical cancer screening program in Morocco: achieve-
ments and challenges. J Med Screen. [cited 2019 Jan 16].
DOI:10.1177/0969141318824627.
[9] Berraho M, Obtel M, Bendahhou K, et al. Sociodemographic fac-
tors and delay in the diagnosis of cervical cancer in Morocco.
Pan Afr Med J. 2012;12:14.
[10] Elmajjaoui S, Ismaili N, El Kacemi H, et al. Epidemiology and out-
come of cervical cancer in National Institute of Morocco. BMC
Womens Health. 2016;16:62.
[11] WHO. WHO j Human Papillomavirus (HPV) position paper. Geneva:
WHO; 2017 [cited 2017, November 4]. Available from: http://www.
who.int/immunization/policy/position_papers/hpv/en/.
[12] Cutts FT, Franceschi S, Goldie S, et al. Human papillomavirus and
HPV vaccines: a review. Bull WHO. 2007;85:719–726.
[13] Tsu V, Murray M, Franceschi S. Human papillomavirus vaccination
in low-resource countries: lack of evidence to support vaccinating
sexually active women. Br J Cancer. 2012;107:1445–1450.
[14] Georgalis L, de Sanjose S, Esnaola M, et al. Present and future of
cervical cancer prevention in Spain: a cost-effectiveness analysis. Eur
J Cancer Prev Off J Eur Cancer Prev Organ ECP. 2016;25:430–439.
[15] Mori~na D, de Sanjose S, Diaz M. Impact of model calibration on
cost-effectiveness analysis of cervical cancer prevention. Sci Rep.
2017;7:17208.
[16] World Population Prospects-Population Division-United Nations.
[cited 2018, April 11]. Available from: https://esa.un.org/unpd/wpp/.
[17] Myers ER, McCrory DC, Nanda K, et al. Mathematical model for
the natural history of human papillomavirus infection and cer-
vical carcinogenesis. Am J Epidemiol. 2000;151:1158–1171.
[18] Torvinen S, Nieminen P, Lehtinen M, et al. Cost effectiveness of
prophylactic HPV 16/18 vaccination in Finland: results from a
modelling exercise. J Med Econ. 2010;13:284–294.
[19] Annemans L, Remy V, Oyee J, et al. Cost-effectiveness evaluation
of a quadrivalent human papillomavirus vaccine in Belgium.
PharmacoEconomics. 2009;27:231–245.
[20] Szucs TD, Largeron N, Dedes KJ, et al. Cost-effectiveness analysis of
adding a quadrivalent HPV vaccine to the cervical cancer screening
programme in Switzerland. Curr Med Res Opin. 2008;24:1473–1483.
[21] Cancer registries, Morocco. [cited 2018, March 23]. Available
from: http://www.irc.ma/en/statistiques/registre-des-cancers/.
[22] Bruni L, Albero G, Serrano B, et al. [Internet]. ICO/IARC
Information Centre on HPV and Cancer (HPV Information Centre).
Human Papillomavirus and Related Diseases in Morocco.
Summary Report 10 December 2018. [cited 2018 Apr]. Available
from: https://www.hpvcentre.net.
[23] Mustafa RA, Santesso N, Khatib R, et al. Systematic reviews and
meta-analyses of the accuracy of HPV tests, visual inspection with
acetic acid, cytology, and colposcopy. Int J Gynaecol Obstet. 2016;
132:259–265.
[24] The World Bank [Internet]. World Development Indicators, WDI online
version. [cited 2019 May] Available from: https://databank.worldbank.
org/data/reports.aspx?source=world-development-indicators.
[25] GAVI alliance. Millions of girls in developing countries to be pro-
tected against cervical cancer thanks to new HPV vaccine deals.
[cited 2017, December 15]. Available from: http://www.gavi.org/
library/news/press-releases/2013/hpv-price-announcement/.
[26] Levin CE, Van Minh H, Odaga J, et al. Delivery cost of human
papillomavirus vaccination of young adolescent girls in Peru,
Uganda and Viet Nam. Bull WHO. 2013;91:585–592.
[27] Kvizhinadze G, Wilson N, Nair N, et al. How much might a society
spend on life-saving interventions at different ages while remain-
ing cost-effective? A case study in a country with detailed data.
Popul. Health Metr. 2015;13:15.
[28] Bertram MY, Lauer JA, De Joncheere K, et al. Cost-effectiveness
thresholds: pros and cons. Bull WHO. 2016;94:925–930.
[29] Marseille E, Larson B, Kazi DS, et al. Thresholds for the cost-effective-
ness of interventions: alternative approaches. Bull WHO. 2015;93:
118–124.
[30] Diaz M, Mori~na D, Rodrıguez-Sales V, et al. Moving towards an
organized cervical cancer screening: costs and impact. Eur J
Public Health. 2018;28:1132–1138.
[31] Kim J, Sharma M, O’Shea M, et al. Model-based impact and cost-
effectiveness of cervical cancer prevention in the Extended
Middle East and North Africa (EMENA). Vaccine. 2013;31:G65–G77.
[32] Diaz M, Kim JJ, Albero G, et al. Health and economic impact of
HPV 16 and 18 vaccination and cervical cancer screening in India.
Br J Cancer. 2008;99:230–238.
[33] Goldie SJ, Diaz M, Kim S-Y, et al. Mathematical models of cervical can-
cer prevention in the Asia Pacific region. Vaccine. 2008;26:M17–29.
[34] Praditsitthikorn N, Teerawattananon Y, Tantivess S, et al. Economic
evaluation of policy options for prevention and control of cervical
cancer in Thailand. PharmacoEconomics. 2011;29:781–806.
[35] Guerrero AM, Genuino AJ, Santillan M, et al. A cost-utility analysis
of cervical cancer screening and human papillomavirus vaccin-
ation in the Philippines. BMC Public Health. 2015;15:730.
[36] Chanthavilay P, Reinharz D, Mayxay M, et al. The economic evalu-
ation of human papillomavirus vaccination strategies against cer-
vical cancer in women in Lao PDR: a mathematical modelling
approach. BMC Health Serv Res. 2016;16:418.
[37] WHO. WHO guidelines for screening and treatment of precancer-
ous lesions for cervical cancer prevention. Geneva: World Health
Organization; 2013.
[38] Toliman PJ, Kaldor JM, Tabrizi SN, et al. Innovative approaches to
cervical cancer screening in low- and middle-income countries.
Climacteric. 2018;21:235–238.
[39] Clendinen C, Zhang Y, Warburton RN, et al. Manufacturing costs of
HPV vaccines for developing countries. Vaccine. 2016;34:5984–5989.
[40] Finocchario-Kessler S, Wexler C, Maloba M, et al. Cervical cancer
prevention and treatment research in Africa: a systematic review
from a public health perspective. BMC Womens Health. 2016;16:29.
[41] McGhan WF, Al M, Doshi JA, et al. The ISPOR good practices for
quality improvement of cost-effectiveness research task force
report. Value Health J Int Soc Pharmacoeconomics Outcomes Res.
2009;12:1086–1099.
[42] Trikalinos TA, Siebert U, Lau J. Decision-analytic modeling to
evaluate benefits and harms of medical tests—uses and limita-
tions. Med Decis Making. 2009;29:E22–E29.
[43] Griebsch I. Economic evaluation in health care: merging theory
with practice. New York: Oxford University Press; 2001.
[44] Ochalek J, Lomas J, Claxton K. Cost per DALY averted thresholds
for low- and middle-income countries - Research Database, The




[45] Shillcutt SD, Walker DG, Goodman CA, et al. Cost effectiveness
in low- and middle-income countries: a review of the debates
surrounding decision rules. PharmacoEconomics. 2009;27:
903–917.
JOURNAL OF MEDICAL ECONOMICS 1159
